Compare NPKI & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | VTYX |
|---|---|---|
| Founded | 1932 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 990.9M |
| IPO Year | N/A | 2021 |
| Metric | NPKI | VTYX |
|---|---|---|
| Price | $14.39 | $13.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 7 |
| Target Price | ★ $14.17 | $13.50 |
| AVG Volume (30 Days) | 619.9K | ★ 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.96 | N/A |
| Revenue Next Year | $13.16 | N/A |
| P/E Ratio | $38.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.76 | $0.90 |
| 52 Week High | $15.85 | $15.34 |
| Indicator | NPKI | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 72.42 |
| Support Level | $13.53 | $13.89 |
| Resistance Level | $14.58 | $14.07 |
| Average True Range (ATR) | 0.70 | 0.03 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 40.23 | 83.33 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.